The case for complement and inflammation in AMD: open questions

Area of Science:

• Ophthalmology
• Immunology
• Genetics

Background:

• The complement cascade is implicated in the pathogenesis of age-related macular degeneration (AMD).
• Genetic data suggest complement activation in AMD is dysregulated and cannot be adequately inhibited.
• Pharmacological targeting of the complement cascade is a potential therapeutic strategy for AMD.

Purpose of the Study:

• To elucidate the precise role of the complement cascade in the pathogenesis of AMD.
• To identify the specific complement components most suitable for therapeutic modulation.
• To address remaining questions regarding complement's involvement in vision-threatening AMD stages like geographic atrophy and choroidal neovascularization.

Main Methods:

• Review of genetic, preclinical, and immunolabeling data.
• Analysis of the complement cascade's involvement in AMD.
• Identification of therapeutic targets within the complement cascade.

Main Results:

• Genetic data indicate complement cascade overactivation in AMD.
• The exact role of complement in geographic atrophy and choroidal neovascularization remains to be determined.
• Optimal complement targets for AMD therapy are yet to be identified.

Conclusions:

• Understanding the complement cascade's role in AMD pathogenesis is crucial for developing effective treatments.
• Further research is required to pinpoint specific complement targets for AMD therapy.
• Clarifying complement's involvement in advanced AMD stages will guide future clinical therapeutics.